Stem Cell Center of Competence ::: Uni Basel, Switzerland
 

 
    Search    
 
  Research
     
 
   
 
 


 
 

 
   

back

   

Home > Research > Topics > Radek Skoda


 

Prof. Radek Skoda

 
 

Prof. Radek Skoda
Department of Biomedicine
University Hospital Basel
Hebelstrasse 20
4031 Basel/Switzerland

 
E-mail Radek.Skoda@unibas.ch
Phone +41 61 265 2272 (direct)
Phone +41 61 265 2324 (assistant)
Fax +41 61 265 3272
 
Homepage
 


 

Radek Skoda is Professor of Molecular Medicine in the Department of Biomedicine of the University of Basel and the University Hospital Basel. His research group "Experimental Hematology" studies the molecular pathogenesis of myeloproliferative neoplasms (MPN) that represent clonal stem cell disorders with a tendency towards leukemic transformation. MPN are characterized by aberrant proliferation of precursors of the myeloid, erythroid and megakaryocytic lineages resulting in elevated blood counts for red cell, platelet and neutrophil granulocytes. Oncogenic driver mutations in the genes for Janus kinase 2 (JAK2), Calreticulin (CALR) or the thrombopoietin receptor (MPL) can be found in >90% of MPN patients, but additional mutations in genes encoding epigenetic regulators or signaling proteins are detectable in some of the patients. His group uses blood samples from MPN patients and mouse models of MPN to investigate how these mutations alter stem cell properties and interact in disease initiation and progression. This work involves functional and molecular analyses of single hematopoietic stem cells.

Radek Skoda is the principal investigator of the StemSysMed project supported by SystemX. His group has collaborations with groups in Basel as well as with the group of Markus Manz in Zurich and Simon Mendez-Ferrer in Madrid.

For additional details, see
https://biomedizin.unibas.ch/nc/research/research-group-details/home/researchgroup/experimental-hematology/


Selected original publications:

  • Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC. (2016). Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 213:1479-96.
     
  • Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, Hao-Shen H, Romanet V, Murakami M, Radimerski T, Dirnhofer S, Skoda RC. (2016). JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood 128:839-51.
     
  • Karow A, Nienhold R, Lundberg P, Peroni E, Putti MC, Randi ML, Skoda RC. (2015). Mutational profile of childhood myeloproliferative neoplasms. Leukemia 29-2407-9.
     
  • Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-She, H, Dirnhofer S, Skoda RC. (2015). Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood 125:2131-40.
     
  • Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, Orkin SH, Manz MG, Skoda RC. (2014). Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F as the sole gene mutation. J Exp Med. 211:2213-30.
     
  • Sánchez-Aguilera A, Arranz L, Martín-Pérez D, García-García A, Stavropoulou V, Kubovcakova L, Isern J, Martín-Salamanca S, Langa X, Skoda RC, Schwaller J, Méndez-Ferrer S. (2014). Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell 15:791-804.
     
  • Arranz L, Sánchez-Aguilera A, Martín-Pérez D, Isern J, Langa X, Tzankov A, Lundberg P, Muntión S, Tzeng YS, Lai DM, Schwaller J, Skoda RC, Méndez-Ferrer S. (2014). Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512:78-81.
     
  • Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC. (2014). Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F driven mouse model of myeloproliferative neoplasms. Blood 123:3943-50.
     
  • Kubovcakova L, Lundberg P, Grisouard J, Hao-Shen H, Romanet V. Andraos R, Murakami M, Dirnhofer S, Wagner KU, Radimerski T, Skoda RC. (2013). Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood 121:1188-99.
     
  • Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC. (2010). Clonal analysis of TET2 and JAK2 Mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115:2003-7.

Selected reviews:

  • Skoda RC, Duek A, Grisouard J. (2015). Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 43:599-608.

  • Skoda RC. (2014). Less Jak2 makes more platelets. Blood 124:2168-9.

  • Skoda RC. Schwaller J. (2011). HiJAKing the methylosome in myeloproliferative disorders. Cancer Cell 19:161-3.

  • Skoda RC. (2010). JAK2 impairs stem cell function? Blood 116:1392-3.